Kliniken der Stadt Koeln gGmbH
- Address
- Ostmerheimer Strasse 200, Merheim, 51109 Cologne, Germany
Kliniken der Stadt Koeln gGmbH - Advanced Oncology Research Center
Kliniken der Stadt Koeln gGmbH is a leading clinical research institution with extensive expertise in oncology clinical trials, particularly focused on advanced and metastatic cancers. The center demonstrates exceptional capabilities in immunotherapy research, targeted therapies, and innovative combination treatment strategies across multiple tumor types.
- Non-Small Cell Lung Cancer (NSCLC) - comprehensive trials spanning early-stage resectable disease to advanced metastatic conditions, including EGFR-mutated, ALK-positive, HER2-mutated, and KRAS G12C-positive variants
- Breast Cancer Research - specialized trials in HER2-positive, triple-negative, and hormone receptor-positive early breast cancer with focus on neoadjuvant and adjuvant therapies
- Pediatric Hematologic Malignancies - international collaborative studies in acute lymphoblastic leukemia (ALL), including relapsed disease and Philadelphia chromosome-positive cases
- Gastrointestinal Oncology - advanced studies in metastatic colorectal cancer, pancreatic adenocarcinoma, and gastric cancer with innovative surgical and systemic approaches
The institution's research portfolio reflects a strong emphasis on precision medicine and biomarker-driven treatment strategies, incorporating next-generation immunotherapies such as checkpoint inhibitors, antibody-drug conjugates, and novel combination regimens. The center actively participates in multinational phase II and III trials evaluating emerging agents including durvalumab, atezolizumab, pembrolizumab, osimertinib, and innovative molecules like tiragolumab, sacituzumab govitecan, and patritumab deruxtecan. Beyond oncology, the center contributes to critical care research in sepsis-related coagulopathy, pulmonary diseases including idiopathic pulmonary fibrosis and viral lung infections, and rare pediatric conditions such as neuroblastoma, rhabdomyosarcoma, and high-risk medulloblastoma, demonstrating comprehensive therapeutic expertise across multiple medical specialties.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 51 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 48 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kliniken der Stadt Koeln gGmbH
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED/GLA 2022-1) | University Of Saarland | Phase III | Recruiting | Apr 2023 | — |
IMP list
lock Showing 1 of 51 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 2 | Unknown | 2022-10-13 | 2024-03-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.